Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HEPA Hepion Pharmaceuticals	$0.07 -16.3%	$0.06	$0.03 ▼ $0.08	$747K	1.52	117,227 shs	29,620 shs
OGEN Oragenics	$1.15 -1.7%	$2.32	$1.03 ▼ $66.00	$946K	0.65	337,518 shs	138,820 shs
PTPI Petros Pharmaceuticals	$0.03 -3.0%	$0.03	$0.02 ▼ $16.25	$907K	1.56	5.19 million shs	431,100 shs
TRVN Trevena	$0.26	$0.88	$0.25 ▼ $7.85	$249K	0.41	2,022 shs	186 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HEPA Hepion Pharmaceuticals	+29.35%	+94.51%	+30.00%	-35.80%	-99.74%
OGEN Oragenics	0.00%	-11.36%	-17.61%	-80.08%	-98.13%
PTPI Petros Pharmaceuticals	+6.76%	+2.04%	+5.26%	-78.57%	-99.62%
TRVN Trevena	0.00%	+4.00%	-72.20%	-78.33%	+26.71%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Company Ownership	Earnings & Valuation
HEPA Hepion Pharmaceuticals	0.3812 of 5 stars	0.0	5.0	0.0	0.6
OGEN Oragenics	0.1092 of 5 stars	0.0	4.0	0.0	0.0
PTPI Petros Pharmaceuticals	0.2111 of 5 stars	0.0	3.0	0.8	0.6
TRVN Trevena	1.5279 of 5 stars	3.0	3.0	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HEPA Hepion Pharmaceuticals	0.00	N/A	N/A	N/A
OGEN Oragenics	0.00	N/A	N/A	N/A
PTPI Petros Pharmaceuticals	0.00	N/A	N/A	N/A
TRVN Trevena	2.00	Hold	$5.00	1,823.08% Upside

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HEPA Hepion Pharmaceuticals	N/A	N/A	N/A	N/A	$1.29 per share	N/A
OGEN Oragenics	N/A	N/A	N/A	N/A	$0.61 per share	N/A
PTPI Petros Pharmaceuticals	$5.11M	0.18	N/A	N/A	$4.04 per share	0.01
TRVN Trevena	$443K	0.56	N/A	N/A	($11.07) per share	-0.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HEPA Hepion Pharmaceuticals	-$48.93M	-$219.00	N/A	∞	N/A	N/A	-812.56%	-207.31%	N/A
OGEN Oragenics	-$20.66M	-$21.42	N/A	∞	N/A	N/A	-2,087.95%	-486.56%	N/A
PTPI Petros Pharmaceuticals	-$8.16M	-$60.87	N/A	∞	N/A	N/A	-78.22%	-23.50%	N/A
TRVN Trevena	-$40.29M	-$47.04	N/A	N/A	N/A	N/A	N/A	-119.55%	N/A

Latest TRVN, OGEN, PTPI, and HEPA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/15/2025	Q1 2025	PTPI Petros Pharmaceuticals	N/A	-$8.46	N/A	-$9.37	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HEPA Hepion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OGEN Oragenics	N/A	N/A	N/A	N/A	N/A
PTPI Petros Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TRVN Trevena	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HEPA Hepion Pharmaceuticals	N/A	1.30	1.30
OGEN Oragenics	N/A	1.93	1.93
PTPI Petros Pharmaceuticals	1.58	0.85	0.74
TRVN Trevena	N/A	2.42	2.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HEPA Hepion Pharmaceuticals	17.24%
OGEN Oragenics	18.71%
PTPI Petros Pharmaceuticals	12.34%
TRVN Trevena	13.56%

Insider Ownership

Company	Insider Ownership
HEPA Hepion Pharmaceuticals	0.06%
OGEN Oragenics	4.90%
PTPI Petros Pharmaceuticals	12.25%
TRVN Trevena	2.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HEPA Hepion Pharmaceuticals	20	11.44 million	6.63 million	No Data
OGEN Oragenics	5	823,000	10.98 million	N/A
PTPI Petros Pharmaceuticals	20	31.16 million	9.93 million	Not Optionable
TRVN Trevena	40	959,000	841,000	Optionable

TRVN, OGEN, PTPI, and HEPA Headlines

Recent News About These Companies

Softball: Conrad Weiser’s Alex Trevena earns statewide player of the year award; 5 other Berks players honored

July 8, 2025 | msn.com

Trevena, Inc. (TRVN) - Yahoo Finance

June 29, 2025 | finance.yahoo.com

Trevena Enters Securities Exchange Agreement with Investor

May 15, 2025 | tipranks.com

Berks sports roundup: Alex Trevena helps Conrad Weiser to 8-5 softball win

April 11, 2025 | readingeagle.comR

Vanessa Hudgens and Oliver Trevena Appear at Expo West for Caliwater

March 9, 2025 | msn.com

JMP Securities downgrades Trevena (TRVN) to a Hold

December 27, 2024 | markets.businessinsider.com

‘Plane’ Actor Oliver Trevena Signs With Untitled Entertainment

December 16, 2024 | yahoo.com

Lyme Regis town councillor John Trevena stand down

December 11, 2024 | bridportnews.co.ukB

Trevena (TRVN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

December 10, 2024 | zacks.com

Trevena appoints new financial chief

November 29, 2024 | investing.com

Trevena Appoints Katrine Sutton as New CFO

November 27, 2024 | tipranks.com

HC Wainwright & Co. Downgrades Trevena (TRVN)

November 16, 2024 | msn.com

Trevena, Inc. Navigates Financial Challenges and Strategic Changes

November 9, 2024 | msn.com

Chester County biopharm firm's latest layoffs impact its C-suite

November 7, 2024 | bizjournals.com

Trevena teeters in dangerous territory, terminating CEO and other execs amid strategic review

November 7, 2024 | fiercebiotech.comF

Trevena Reports Third Quarter 2024 Results and Provides Business Update

November 7, 2024 | globenewswire.com

Why Trevena (TRVN) Stock Is Down 43% Today

October 8, 2024 | msn.com

Trevena, Inc. Faces Delisting from Nasdaq

October 6, 2024 | msn.com

Trevena Announces Receipt of Nasdaq Delisting Notification

October 4, 2024 | globenewswire.com

Learn to Evaluate (TRVN) using the Charts

September 16, 2024 | news.stocktradersdaily.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TRVN, OGEN, PTPI, and HEPA Company Descriptions

Hepion Pharmaceuticals NASDAQ:HEPA

$0.07 -0.01 (-16.28%)

As of 02:23 PM Eastern

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Oragenics NYSE:OGEN

$1.15 -0.02 (-1.71%)

Closing price 04:00 PM Eastern

Extended Trading

$1.16 +0.01 (+0.43%)

As of 07:59 PM Eastern

Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

Petros Pharmaceuticals NASDAQ:PTPI

$0.03 0.00 (-3.00%)

As of 03:59 PM Eastern

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

Trevena NASDAQ:TRVN

$0.26 0.00 (0.00%)

As of 08/12/2025

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time